Joon Lee
Stock Analyst at Truist Financial
(4.97)
# 84
Out of 4,676 analysts
518
Total ratings
59.9%
Success rate
38.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joon Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VYGR Voyager Therapeutics | Maintained: Buy | n/a | $3.48 | - | 16 | Mar 17, 2026 | |
| EDIT Editas Medicine | Maintained: Hold | n/a | $3.28 | - | 22 | Mar 17, 2026 | |
| SLDB Solid Biosciences | Maintained: Buy | n/a | $9.89 | - | 11 | Mar 13, 2026 | |
| PRAX Praxis Precision Medicines | Reiterated: Buy | $700 | $368.02 | +90.21% | 29 | Mar 12, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintained: Buy | $525 | $552.85 | -5.04% | 16 | Mar 11, 2026 | |
| ANAB AnaptysBio | Maintained: Hold | $50 | $58.37 | -14.34% | 30 | Mar 9, 2026 | |
| VKTX Viking Therapeutics | Maintained: Buy | n/a | $34.17 | - | 43 | Mar 5, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintained: Buy | n/a | $66.12 | - | 14 | Mar 3, 2026 | |
| CORT Corcept Therapeutics | Maintained: Buy | n/a | $123.57 | - | 38 | Mar 2, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Buy | n/a | $13.51 | - | 29 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $60.90 | - | 24 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $73.47 | - | 11 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.25 | - | 41 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $49.21 | - | 3 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $260.23 | - | 26 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $205.48 | - | 37 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $90 → $76 | $26.46 | +187.23% | 29 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $51.17 | - | 2 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.16 | - | 8 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $6.20 | - | 24 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $1,019.49 | n/a | 38 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $11.68 | n/a | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $8.56 | n/a | 10 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $100 → $65 | $9.60 | n/a | 5 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $7 → $4 | $4.59 | n/a | 4 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $4.00 | n/a | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $19.29 | n/a | 1 | Aug 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $76 | $51.05 | n/a | 1 | Jun 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $6.21 | n/a | 1 | Jun 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $18.92 | n/a | 1 | Aug 8, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $33 | $30.57 | n/a | 1 | Aug 7, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $1.23 | n/a | 1 | Jul 28, 2014 |
Voyager Therapeutics
Mar 17, 2026
Maintained: Buy
Price Target: n/a
Current: $3.48
Upside: -
Editas Medicine
Mar 17, 2026
Maintained: Hold
Price Target: n/a
Current: $3.28
Upside: -
Solid Biosciences
Mar 13, 2026
Maintained: Buy
Price Target: n/a
Current: $9.89
Upside: -
Praxis Precision Medicines
Mar 12, 2026
Reiterated: Buy
Price Target: $700
Current: $368.02
Upside: +90.21%
Vertex Pharmaceuticals
Mar 11, 2026
Maintained: Buy
Price Target: $525
Current: $552.85
Upside: -5.04%
AnaptysBio
Mar 9, 2026
Maintained: Hold
Price Target: $50
Current: $58.37
Upside: -14.34%
Viking Therapeutics
Mar 5, 2026
Maintained: Buy
Price Target: n/a
Current: $34.17
Upside: -
BioMarin Pharmaceutical
Mar 3, 2026
Maintained: Buy
Price Target: n/a
Current: $66.12
Upside: -
Corcept Therapeutics
Mar 2, 2026
Maintained: Buy
Price Target: n/a
Current: $123.57
Upside: -
Intellia Therapeutics
Mar 2, 2026
Maintained: Buy
Price Target: n/a
Current: $13.51
Upside: -
Mar 2, 2026
Maintained: Buy
Price Target: n/a
Current: $60.90
Upside: -
Feb 27, 2026
Maintained: Buy
Price Target: n/a
Current: $73.47
Upside: -
Feb 27, 2026
Reiterated: Buy
Price Target: n/a
Current: $5.25
Upside: -
Feb 26, 2026
Maintained: Buy
Price Target: n/a
Current: $49.21
Upside: -
Feb 25, 2026
Maintained: Buy
Price Target: n/a
Current: $260.23
Upside: -
Feb 24, 2026
Maintained: Buy
Price Target: n/a
Current: $205.48
Upside: -
Feb 13, 2026
Maintained: Buy
Price Target: $90 → $76
Current: $26.46
Upside: +187.23%
Nov 10, 2025
Maintained: Buy
Price Target: n/a
Current: $51.17
Upside: -
Nov 6, 2025
Maintained: Buy
Price Target: n/a
Current: $4.16
Upside: -
Nov 5, 2025
Maintained: Buy
Price Target: n/a
Current: $6.20
Upside: -
Aug 1, 2025
Maintained: Buy
Price Target: n/a
Current: $1,019.49
Upside: n/a
Dec 4, 2024
Rated: Buy
Price Target: n/a
Current: $11.68
Upside: n/a
Nov 14, 2023
Maintained: Buy
Price Target: $18
Current: $8.56
Upside: n/a
Jan 17, 2023
Maintained: Buy
Price Target: $100 → $65
Current: $9.60
Upside: n/a
Dec 8, 2022
Maintained: Hold
Price Target: $7 → $4
Current: $4.59
Upside: n/a
May 5, 2022
Reiterated: Buy
Price Target: $14
Current: $4.00
Upside: n/a
Aug 8, 2019
Maintained: Buy
Price Target: $10
Current: $19.29
Upside: n/a
Jun 19, 2019
Initiated Coverage: Buy
Price Target: $76
Current: $51.05
Upside: n/a
Jun 19, 2019
Initiated Coverage: Buy
Price Target: $20
Current: $6.21
Upside: n/a
Aug 8, 2014
Maintained: Buy
Price Target: n/a
Current: $18.92
Upside: n/a
Aug 7, 2014
Reiterated: Buy
Price Target: $33
Current: $30.57
Upside: n/a
Jul 28, 2014
Maintained: Buy
Price Target: $14
Current: $1.23
Upside: n/a